rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Prime Medicine, Inc.

PRME · Nasdaq

Health CareBiotechnologyAbove a falling average

PRME stood above a rising 150-day average in 9 of the last 52 weekly readings, and has been out of that trend for the last 38 weeks. It is 17.0% above that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).

Statistics

Rotation
Above a falling average
Weeks in an uptrend
out for 38
Industry in uptrend
18% -14 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
177 (-3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 9 of 52 weeks.

21 Apr – 20 Oct
18%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$33.7MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders177-3 on the quarter
New · exited23 · 26
Reported value$372.1M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Alphabet Inc.unchanged · filed 7 Aug 202616,562,498$61.1M00.0%
BlackRock, Inc.added · filed 7 Aug 20269,602,041$35.4M+1,100,333+12.9%
ARK Investment Management LLCadded · filed 14 Aug 20268,348,746$30.8M+2,101,919+33.6%
STATE STREET CORPadded · filed 7 Aug 20267,576,460$28.0M+1,231,335+19.4%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20264,522,640$16.7M+48,478+1.1%
Balyasny Asset Management L.P.reduced · filed 14 Aug 20263,969,082$14.6M-154,283−3.7%
GOLDMAN SACHS GROUP INCadded · filed 14 Aug 20263,430,518$12.7M+2,460,093+253.5%
Casdin Capital, LLCunchanged · filed 14 Aug 20263,167,175$11.7M00.0%
Woodline Partners LPadded · filed 14 Aug 20263,003,904$11.1M+5910.0%
UBS Group AGreduced · filed 13 Aug 20262,794,689$10.3M-93,729−3.2%
31 Mar 2023 – 30 Jun 2026
63120176Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

David P. Schenkein Company insiderDirector · last 5 Jun 20260 · 0
Jeffrey D. Marrazzo Company insiderDirector · last 5 Jun 20260 · 0
Kaye I. Foster-Cheek Company insiderDirector · last 5 Jun 20260 · 0
Michael Aaron Kelly Company insiderDirector · last 5 Jun 20260 · 0
Robert Nelsen Company insiderDirector, 10% owner · last 5 Jun 20263 · 0
Thomas Cahill Company insiderDirector · last 5 Jun 20261 · 0
Wendy Chung Company insiderDirector · last 5 Jun 20260 · 0
Svetlana Ni Makhni Company insiderChief Financial Officer · last 16 Apr 20260 · 0
Allan Reine Company insiderChief Executive Officer · last 26 Feb 20261 · 0
Ann L. Lee Company insiderChief Technical Officer · last 23 Feb 20261 · 0
Carman Alenson Company insiderOfficer · last 23 Feb 20260 · 0
Alphabet Inc. Company insider10% owner · last 1 Aug 20251 · 6

Same industry

MRNA ModernaLeading+167%
ENTX Entera BioLeading+52%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-68.2%
Share count trendFY 2025 · to 20 Feb 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$63.0M
Free cash flowFY 2025 · to 31 Dec 2025−$167.1M

Analyst forecasts

No analyst forecasts yet.